Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A Book on Zolpidem Effects Published

8 Dec 2008 11:15

RNS Number : 7046J
ReGen Therapeutics PLC
08 December 2008
 



8th December 2008

ReGen Therapeutics Plc <AIM: RGT, OTCQX: REGUY> Announces Publication of a Book on the Effects of Zolpidem Following Brain Damage.

ReGen Therapeutics Plc ("ReGen" or the "Company") announces that its scientific adviser Dr Ralf Clauss will shortly publish a book on the effects of zolpidem following brain damage.

 

Entitled 'Hope in Brain Damage' (ISBN 97895594093), the book is scheduled for publication on 11th January 2009 and is already available to order at large bookstores, including Waterstones, Amazon, Blackwell and WH Smith.

 

'Hope in Brain Damage' is the fascinating story of Louis Viljoen, a young man categorized as being in a vegetative state after a road accident, but who regained consciousness, three years later following treatment with zolpidem. The story follows Louis in his progress, since doctors treating him in South Africa discovered that the drug appeared to have a dramatic and sustainable effect in reversing cognitive and functional debilities associated with brain damage. 

 

The book has been written by Dr Ralf Clauss, who developed the treatment in collaboration with Dr Wally Nel of the Walko Medical Centre in Springs, South Africa. The use of zolpidem in various brain damage conditions including stroke and birth injury is described, ethical considerations are raised and new therapies for patients with brain damage are discussed.

 

ReGen acquired the rights to the further development of this potential new use for zolpidem from Sciencom Ltd in 2006. Percy Lomax, Chairman & Chief Executive of ReGen commented:-

"The publication of this book is a tribute to the hard work and dedication of its author and his co-workers. The discovery of this alternative use of zolpidem for a condition that is both largely untreatable and a terrible drain on the families of affected individuals was remarkable and is something that should be celebrated. We are confident that the wider circulation of this fascinating "inside story" of Louis Viljoen's progress will bring hope to everyone with an interest in this area".

For further information:

Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920

Roland Cornish/Felicity Geidt

Beaumont Cornish Limited

Tel: 020 7628 3396

David Scott/Nick Bealer

Alexander David

Tel: 020 7448 9820

Adrian Duffield/Jon Davies

College Hill Associates

Tel: 020 7457 2020

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAILFLLFSLTIIT
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.